| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Oleg Dyachok, Yegor Isakov, Jenny Sågetorp, Anders Tenghol. Oscillations of cyclic AMP in hormone-stimulated insulin-secreting beta-cells. Nature. vol 439. issue 7074. 2006-02-14. PMID:16421574. |
in pancreatic beta-cells, camp potentiates ca2+-dependent exocytosis and mediates the stimulation of insulin release exerted by the hormones glucagon and glucagon-like peptide-1 (glp-1) (refs 4, 5-6). |
2006-02-14 |
2023-08-12 |
Not clear |
| J Schirra, M Nicolaus, R Roggel, M Katschinski, M Storr, H J Woerle, B Gök. Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans. Gut. vol 55. issue 2. 2006-02-13. PMID:15985560. |
exogenous use of the intestinal hormone glucagon-like peptide 1 (glp-1) lowers glycaemia by stimulation of insulin, inhibition of glucagon, and delay of gastric emptying. |
2006-02-13 |
2023-08-12 |
Not clear |
| K K Sidhu, R C Fowkes, R H Skelly, J M Burri. Exogenous expression of glucagon-like peptide 1 receptor and human insulin in AtT-20 corticotrophs confers cAMP-mediated gene transcription and insulin secretion. The Journal of endocrinology. vol 187. issue 3. 2006-02-09. PMID:16423821. |
however, using an adenoviral expression system to infect att-20 cells with glp-1r and the preproinsulin gene (including 120 bp of its own promoter) resulted in a 6.4 +/- 0.6-fold increase in camp and a 4.9 +/- 0.8-fold increase in insulin secretion in response to 100 nm glp-1. |
2006-02-09 |
2023-08-12 |
human |
| David A D'Alessio, Darleen A Sandoval, Randy J Seele. New ways in which GLP-1 can regulate glucose homeostasis. The Journal of clinical investigation. vol 115. issue 12. 2006-02-06. PMID:16322789. |
provide clear evidence that glp-1 signaling in the cns is also linked to the control of peripheral glucose homeostasis by inhibiting non-insulin-mediated glucose uptake by muscle and increasing insulin secretion from the pancreas. |
2006-02-06 |
2023-08-12 |
Not clear |
| Claude Knauf, Patrice D Cani, Christophe Perrin, Miguel A Iglesias, Jean François Maury, Elodie Bernard, Fadilha Benhamed, Thierry Grémeaux, Daniel J Drucker, C Ronald Kahn, Jean Girard, Jean François Tanti, Nathalie M Delzenne, Catherine Postic, Rémy Burceli. Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. The Journal of clinical investigation. vol 115. issue 12. 2006-02-06. PMID:16322793. |
intestinal glucagon-like peptide-1 (glp-1) is a hormone released into the hepatoportal circulation that stimulates pancreatic insulin secretion. |
2006-02-06 |
2023-08-12 |
mouse |
| Claude Knauf, Patrice D Cani, Christophe Perrin, Miguel A Iglesias, Jean François Maury, Elodie Bernard, Fadilha Benhamed, Thierry Grémeaux, Daniel J Drucker, C Ronald Kahn, Jean Girard, Jean François Tanti, Nathalie M Delzenne, Catherine Postic, Rémy Burceli. Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. The Journal of clinical investigation. vol 115. issue 12. 2006-02-06. PMID:16322793. |
our data show that during hyperglycemia, brain glp-1 inhibited muscle glucose utilization and increased insulin secretion to favor hepatic glycogen stores, preparing efficiently for the next fasting state. |
2006-02-06 |
2023-08-12 |
mouse |
| B E Dunning, J E Foley, B Ahré. Alpha cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia. vol 48. issue 9. 2006-02-03. PMID:16132964. |
however, recognition that the incretin hormone glucagon-like peptide-1 (glp-1) exerts opposing effects on glucagon and insulin secretion has revived interest in glucagon, the neglected partner of insulin, in the bihormonal hypothesis. |
2006-02-03 |
2023-08-12 |
human |
| Hiroshi Yamamoto, Tsuyoshi Mori, Hiroshi Tsuchihashi, Hiroya Akabori, Hiroyuki Naito, Tohru Tan. A possible role of GLP-1 in the pathophysiology of early dumping syndrome. Digestive diseases and sciences. vol 50. issue 12. 2006-02-03. PMID:16416173. |
in 11 patients after gastrectomy and 14 controls, blood pressure, heart rate, and plasma concentrations of norepinephrine, epinephrine, glp-1, glucagon, insulin, and glucose were measured after oral glucose. |
2006-02-03 |
2023-08-12 |
Not clear |
| C M Rotella, L Pala, E Mannucc. Glucagon-like peptide 1 (GLP-1) and metabolic diseases. Journal of endocrinological investigation. vol 28. issue 8. 2006-01-31. PMID:16277173. |
glucagon-like peptide-1 (glp-1) is a gastrointestinal hormone, mainly secreted after meals, which enhances glucose-induced insulin secretion and induces satiety. |
2006-01-31 |
2023-08-12 |
human |
| C M Rotella, L Pala, E Mannucc. Glucagon-like peptide 1 (GLP-1) and metabolic diseases. Journal of endocrinological investigation. vol 28. issue 8. 2006-01-31. PMID:16277173. |
the reduction of post-prandial circulating active glp-1 in type 2 diabetic subjects, as a consequence of chronic hyperglycemia, could contribute to the reduction of early post-prandial insulin secretion; in fact, the administration of glp-1 receptor antagonists to healthy volunteers elicits both an impairment of meal-induced insulin secretion and an increase of post-prandial glycemia similar to that observed in type 2 diabetes. |
2006-01-31 |
2023-08-12 |
human |
| David A D'Alessio, Torsten P Vah. Utilizing the GLP-1 signaling system to treat diabetes: sorting through the pharmacologic approaches. Current diabetes reports. vol 5. issue 5. 2006-01-26. PMID:16188169. |
glucagon-like peptide-1 (glp-1) is an intestinal hormone that promotes glucose homeostasis through the regulation of insulin and glucagon secretion, gastric emptying, and food intake. |
2006-01-26 |
2023-08-12 |
Not clear |
| Bo Ahrén, Maria Sörhede Winzell, Bryan Burkey, Thomas E Hughe. Beta-cell expression of a dominant-negative HNF-1alpha compromises the ability of inhibition of dipeptidyl peptidase-4 to elicit a long-term augmentation of insulin secretion in mice. European journal of pharmacology. vol 521. issue 1-3. 2006-01-25. PMID:16171801. |
glucagon-like peptide-1 (glp-1) has long-term effects on pancreatic islets by increasing the insulin secretory capacity and beta cell mass. |
2006-01-25 |
2023-08-12 |
mouse |
| Bo Ahrén, Maria Sörhede Winzell, Bryan Burkey, Thomas E Hughe. Beta-cell expression of a dominant-negative HNF-1alpha compromises the ability of inhibition of dipeptidyl peptidase-4 to elicit a long-term augmentation of insulin secretion in mice. European journal of pharmacology. vol 521. issue 1-3. 2006-01-25. PMID:16171801. |
we examined whether prevention of inactivation of glp-1 by inhibiting dipeptidyl peptidase-4 (dpp-4) is sufficient to promote long-term augmentation of glucose-stimulated insulin secretion. |
2006-01-25 |
2023-08-12 |
mouse |
| B F Burkey, X Li, L Bolognese, B Balkan, M Mone, M Russell, T E Hughes, P R Wan. Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats. The Journal of pharmacology and experimental therapeutics. vol 315. issue 2. 2006-01-12. PMID:16027230. |
this study examined acute (single dose) and chronic (once-a-day dosing for 21 days) effects of the dpp-4 inhibitor vildagliptin (0.03-10 mg/kg) on plasma dpp-4 activity, intact glp-1, glucose, and insulin after an oral glucose load in insulin-resistant zucker fatty rats and acute effects in mildly insulin-resistant high-fat-fed normal rats. |
2006-01-12 |
2023-08-12 |
rat |
| Suna Choi, Seungjoon Oh, Minhyung Lee, Sung Wan Ki. Glucagon-like peptide-1 plasmid construction and delivery for the treatment of type 2 diabetes. Molecular therapy : the journal of the American Society of Gene Therapy. vol 12. issue 5. 2006-01-06. PMID:16039908. |
it has been proposed that glp-1 can be used as a new treatment for type 2 diabetes mellitus because it acts to augment insulin secretion and its effectiveness is maintained in type 2 diabetic patients. |
2006-01-06 |
2023-08-12 |
mouse |
| Inga Thrainsdottir, Klas Malmberg, Arne Olsson, Mark Gutniak, Lars Rydé. Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure. Diabetes & vascular disease research. vol 1. issue 1. 2005-12-28. PMID:16305055. |
glucagon-like peptide-1 (glp-1) causes glucose-dependent secretion of insulin, improving glycaemic control. |
2005-12-28 |
2023-08-12 |
Not clear |
| Nieves González, Verónica Sancho, Antonio Martín-Duce, Pilar Tornero-Esteban, Isabel Valverde, Willy J Malaisse, María L Villanueva-Peñacarrill. GLP-1 signalling and effects on glucose metabolism in myocytes from type 2 diabetic patients. International journal of molecular medicine. vol 16. issue 4. 2005-12-21. PMID:16142415. |
the major aims of the present study were i) to investigate the possible extension of this knowledge to myocytes obtained from type 2 diabetic patients, ii) to compare in these patients the response to glp-1, insulin or the structurally related glp-1 peptides, exendin (1-39)amide and exendin(9-39)amide, and iii) to explore possible differences in the responsiveness to these agents between normal and diabetic subjects. |
2005-12-21 |
2023-08-12 |
human |
| Nieves González, Verónica Sancho, Antonio Martín-Duce, Pilar Tornero-Esteban, Isabel Valverde, Willy J Malaisse, María L Villanueva-Peñacarrill. GLP-1 signalling and effects on glucose metabolism in myocytes from type 2 diabetic patients. International journal of molecular medicine. vol 16. issue 4. 2005-12-21. PMID:16142415. |
nevertheless, significant differences in glucose transport and metabolism parameters were observed in the diabetic patients vs. normal subjects: in the diabetic patients, basal 2-deoxy-glucose uptake and glycogen synthase a activity were lower, accompanied by a similar increasing effect of glp-1 or insulin; yet, the basal value for glycogen synthesis was higher, coinciding with a lesser relative increment in response to glp-1 or insulin. |
2005-12-21 |
2023-08-12 |
human |
| C Mark B Edward. The GLP-1 system as a therapeutic target. Annals of medicine. vol 37. issue 5. 2005-12-21. PMID:16179267. |
glp-1 stimulates insulin secretion, delays gastric emptying, decreases glucagon levels and reduces appetite, all resulting in a fall in plasma glucose concentrations. |
2005-12-21 |
2023-08-12 |
Not clear |
| B Ahrén, K Thomaseth, G Pacin. Reduced insulin clearance contributes to the increased insulin levels after administration of glucagon-like peptide 1 in mice. Diabetologia. vol 48. issue 10. 2005-12-20. PMID:16132949. |
glucagon-like peptide-1 (glp-1) is known to be a potent stimulator of insulin secretion. |
2005-12-20 |
2023-08-12 |
mouse |